A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study

Guidelines on Testicular Cancer: 2015 Update

“…For metastatic seminoma, very limited data are available from randomised trials and they indicate that a cisplatin-based regimen is preferable to carboplatin chemotherapy [59]. Recent data indicate that EP Â 4 results in cure in almost all cases of seminomatous germ-cell cancers with good prognosis [60]. Standard treatment in this setting should therefore be BEP Â 3 or EP Â 4.…”

Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation

“…The first is a French risk-adapted study whereby 24 patients with intermediate-risk seminoma received 4 cycles of VIP chemotherapy, and the 3-year PFS rate was 83% [12]. The second is a currently recruiting U.S. phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) for modified intermediate-prognosis (i.e., LDH modified to Z3Â ULN) and poor-prognosis GCT, where the estimated 3-year PFS rate was 87% for the intermediate-risk cohort, despite the short median follow-up at the time of interim analysis [13].…”

A phase II study of carboplatin AUC-10 guided by positron emission tomography–defined metabolic response in metastatic seminoma

“…12 For more advanced disease (2C and above) combination chemotherapy is usually used. 13 To date carboplatin at least in the adjuvant setting has not been associated with secondary malignancies or raised cardiovascular riskunlike the situation with combination cisplatin based therapies. A majority of patients failing single agent chemotherapy can be salvaged with combination chemotherapy (most frequently BEP).…”